Funding Approved for Major New Study on the Value of PET Scans for Alzheimer's Disease
By MedImaging International staff writers Posted on 20 Apr 2015 |
A new four-year trial with an estimated budget of USD 100 million has been announced by the US Alzheimer's Association (Chicago, IL, USA), and the American College of Radiology (ACR; Reston, VA, USA).
The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study will try to assess the value of diagnosing Alzheimer's disease, and other dementia-related disorders using Positron Emission Tomography (PET) brain scans. A total of 18,488 people aged 65 and older, from 200 sites in the US, will take part in the study.
The study will investigate the impact of amyloid PET on short-term patient management by comparing planned Alzheimer's disease management before PET and actual management after PET. The second aim of the study is to compare medical outcomes after 1 year for patients enrolled in the study, with a matched control group of patients who have never had amyloid PET imaging.
Gil D. Rabinovici, MD, IDEAS study chair, said, "We believe the study will show that, in diagnostically uncertain cases, knowledge of amyloid status will lead to significant changes in patient management—such as earlier counseling and prescription of more appropriate drugs—that will translate into improved long-term outcomes."
Related Links:
American College of Radiology
US Alzheimer's Association
The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study will try to assess the value of diagnosing Alzheimer's disease, and other dementia-related disorders using Positron Emission Tomography (PET) brain scans. A total of 18,488 people aged 65 and older, from 200 sites in the US, will take part in the study.
The study will investigate the impact of amyloid PET on short-term patient management by comparing planned Alzheimer's disease management before PET and actual management after PET. The second aim of the study is to compare medical outcomes after 1 year for patients enrolled in the study, with a matched control group of patients who have never had amyloid PET imaging.
Gil D. Rabinovici, MD, IDEAS study chair, said, "We believe the study will show that, in diagnostically uncertain cases, knowledge of amyloid status will lead to significant changes in patient management—such as earlier counseling and prescription of more appropriate drugs—that will translate into improved long-term outcomes."
Related Links:
American College of Radiology
US Alzheimer's Association
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure